CapmatinibAcquired MET D1228H mutation: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2026卷 / 1期
关键词：
D O I：
10.1007/s40278-024-66936-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：73 / 73
相关论文
共 50 条
  • [21] A Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient with Acquired MET Amplification
    Liang, Y.
    Chen, Q.
    Lin, Y.
    Liu, H.
    Qiu, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S890 - S890
  • [22] Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report
    Leyrat, Brice
    Durando, Xavier
    Veyssiere, Hugo
    Bernadach, Maureen
    ONCOTARGETS AND THERAPY, 2021, 14 : 3949 - 3958
  • [23] Non-small cell lung cancer with MET exon 14 skip mutation: case report
    Clough, Wolfgang
    Al Jaberi, Mira
    Dalia, Samir
    ANNALS OF TRANSLATIONAL MEDICINE, 2022,
  • [24] VITREOUS AMYLOIDOSIS IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY - REPORT OF A CASE WITH THE VAL30MET TRANSTHYRETIN MUTATION
    CIULLA, TA
    TOLENTINO, F
    MORROW, JF
    DRYJA, TP
    SURVEY OF OPHTHALMOLOGY, 1995, 40 (03) : 197 - 206
  • [25] Mucoepidermoid Carcinoma of the Lung Harboring MET Exon 14 Skipping Mutation Treated With Tepotinib: A Case Report
    Inno, Alessandro
    Bogina, Giuseppe
    Settanni, Giulio
    Foti, Giovanni
    Tessari, Roberto
    Gori, Stefania
    JCO PRECISION ONCOLOGY, 2023, 7
  • [26] Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
    Piper-Vallillo, Andrew J.
    Halbert, Brian T.
    Rangachari, Deepa
    Kobayashi, Susumu S.
    Costa, Daniel B.
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [27] Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion
    Dong, Su-Su
    Dong, Wen
    Tan, Ya-Fen
    Xiao, Qiang
    Wang, Tian-Li
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [28] Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
    Umeda, Yukihiro
    Kimura, Satomi
    Kimura, Junya
    Imamura, Yoshiaki
    Ishizuka, Tamotsu
    THORACIC CANCER, 2025, 16 (02)
  • [29] Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report
    Li, Rongzhen
    Liu, Xiaoyan
    Xu, Yan
    Zhao, Jing
    Zhong, Wei
    Gao, Xiaoxing
    Chen, Minjiang
    Wang, Mengzhao
    THORACIC CANCER, 2024, 15 (32) : 2339 - 2343
  • [30] When Patient Expectations Are Not Met: A Case Report
    Sadowsky, Aaron
    Porat, Yoad
    Faruki, Adeel A.
    Vitter, Jillian S.
    A & A PRACTICE, 2023, 17 (06) : E01686
12345